 |
Atezolizumab + Bevacizumab |
|---|---|
| Trade Name | |
| Orphan Indication | Hepatocellular Carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 2018-01-08 00:00:00 |
| Sponsor | Genentech, Inc.;1 DNA Way, Mail Stop # 355e;South San Francisco, California, 94080 |
| |
Atezolizumab + Bevacizumab |
|---|---|
| Trade Name | |
| Orphan Indication | Hepatocellular Carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 2018-01-08 00:00:00 |
| Sponsor | Genentech, Inc.;1 DNA Way, Mail Stop # 355e;South San Francisco, California, 94080 |